22 research outputs found
Recommended from our members
Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma
Abstract: The identification of cancer-promoting genetic alterations is challenging particularly in highly unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we describe a machine learning algorithm to identify cancer genes in individual patients considering all types of damaging alterations simultaneously. Analysing 261 EACs from the OCCAMS Consortium, we discover helper genes that, alongside well-known drivers, promote cancer. We confirm the robustness of our approach in 107 additional EACs. Unlike recurrent alterations of known drivers, these cancer helper genes are rare or patient-specific. However, they converge towards perturbations of well-known cancer processes. Recurrence of the same process perturbations, rather than individual genes, divides EACs into six clusters differing in their molecular and clinical features. Experimentally mimicking the alterations of predicted helper genes in cancer and pre-cancer cells validates their contribution to disease progression, while reverting their alterations reveals EAC acquired dependencies that can be exploited in therapy
Patients’ perspectives on opt-out consent for observational research:systematic review and focus group
SP2.2.4 Structured prehabilitation reduces physical deconditioning and improves emotional and physical well-being during neo-adjuvant chemotherapy prior to surgery for oesophageal cancer
This is an accepted manuscript of an abstract published by the British Journal of Surgery Society and OUP on 09/08/2022, available online: https://doi.org/10.1093/bjs/znac247.026 The accepted version of the publication may differ from the final published version.Published versio
Extent of lymphadenectomy and prognosis after esophageal cancer surgery
Importance: The prognostic role of the extent of lymphadenectomy during surgery
for esophageal cancer is uncertain and requires clarification.
Objective: To clarify whether the number of removed lymph nodes influences mortality following
surgery for esophageal cancer.
Design, Setting, and Participants: Conducted from
January 1, 2000, to January 31, 2014, this was a cohort study of patients who
underwent esophagectomy for cancer in 2000-2012 at a high-volume hospital for
esophageal cancer surgery, with follow-up until 2014.
Exposures: The main exposure was the number of resected lymph nodes. Secondary exposures were the
number of metastatic lymph nodes and positive to negative lymph node ratio.
Main
Outcomes and Measures: The independent role of the extent of lymphadenectomy in
relation to all-cause and disease-specific 5-year mortality was analyzed using
Cox proportional hazard regression models, providing hazard ratios (HRs) with 95%
CIs. The HRs were adjusted for age, pathological T category, tumor
differentiation, margin status, calendar period of surgery, and response to
preoperative chemotherapy.
Results: Among 606 included patients, 506 (83.5%) had
adenocarcinoma of the esophagus, 323 (53%) died within 5 years of surgery, and
235 (39%) died of tumor recurrence. The extent of lymphadenectomy was not
statistically significantly associated with all-cause or disease-specific
mortality, independent of the categorization of lymphadenectomy or stratification
for T category, calendar period, or chemotherapy. Patients in the fourth quartile
of the number of removed nodes (21-52 nodes) did not demonstrate a statistically
significant reduction in all-cause 5-year mortality compared with those in the
lowest quartile (0-10 nodes) (HR, 0.86; 95% CI, 0.63-1.17), particularly not in
the most recent calendar period (HR, 0.98; 95% CI, 0.57-1.66 for years
2007-2012). A greater number of metastatic nodes and a higher positive to
negative node ratio was associated with increased mortality rates, and these
associations showed dose-response associations.
Conclusions and Relevance: This
study indicated that the extent of lymphadenectomy during surgery for esophageal
cancer might not influence 5-year all-cause or disease-specific survival. These
results challenge current clinical guidelines.Swedish Research CancerPublishe
The Impact of COVID-19 on Clinical Nurse Specialists and Patients With Cancer:A Pan-Specialty Cross-sectional Survey
PURPOSE/AIMS: Uptake and delivery of cancer services across the United Kingdom have been significantly impacted by the COVID-19 pandemic. This study aimed to understand the impact of the pandemic on the working practices of clinical nurse specialists and their patient interactions across different cancer specialties. DESIGN: We performed a cross-sectional survey exploring nurses' experiences of delivering care during the pandemic, as well as their perceptions of the concerns that cancer patients were experiencing. METHODS: Clinical nurse specialists working in London cancer services were invited to complete an online questionnaire. Nurses' experiences and their perceptions of patients' concerns were analyzed descriptively. RESULTS: Fifty-four nurses participated. Almost half had been redeployed to other clinical areas during the pandemic (n = 19). COVID-19 discussions added 5 to 10 minutes on average to most consultations, with nurses either working longer/unpaid hours (34%) or spending less time talking to patients about cancer (39%) to deal with this. Approximately 50% of nurses would have liked additional information and support from their hospital. CONCLUSIONS: Clinical nurse specialist time and resources have been stretched during the COVID-19 pandemic. Hospitals need to work with nursing staff to ensure the specific information needs of cancer patients are being met
The Impact of COVID-19 on Clinical Nurse Specialists and Patients With Cancer: A Pan-Specialty Cross-sectional Survey
PURPOSE/AIMS: Uptake and delivery of cancer services across the United Kingdom have been significantly impacted by the COVID-19 pandemic. This study aimed to understand the impact of the pandemic on the working practices of clinical nurse specialists and their patient interactions across different cancer specialties. DESIGN: We performed a cross-sectional survey exploring nurses' experiences of delivering care during the pandemic, as well as their perceptions of the concerns that cancer patients were experiencing. METHODS: Clinical nurse specialists working in London cancer services were invited to complete an online questionnaire. Nurses' experiences and their perceptions of patients' concerns were analyzed descriptively. RESULTS: Fifty-four nurses participated. Almost half had been redeployed to other clinical areas during the pandemic (n = 19). COVID-19 discussions added 5 to 10 minutes on average to most consultations, with nurses either working longer/unpaid hours (34%) or spending less time talking to patients about cancer (39%) to deal with this. Approximately 50% of nurses would have liked additional information and support from their hospital. CONCLUSIONS: Clinical nurse specialist time and resources have been stretched during the COVID-19 pandemic. Hospitals need to work with nursing staff to ensure the specific information needs of cancer patients are being met
Analysis of outcomes of a transoral circular stapled anastomosis following major upper gastrointestinal cancer resection
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction
Purpose Neoadjuvant chemotherapy is established in the management of most resectable esophageal and esophagogastric junction adenocarcinomas. However, assessing the downstaging effects of chemotherapy and predicting response to treatment remain challenging, and the relative importance of tumor stage before and after chemotherapy is debatable. Methods We analyzed consecutive resections for esophageal or esophagogastric junction adenocarcinomas performed at two high-volume cancer centers in London between 2000 and 2010. After standard investigations and multidisciplinary team consensus, all patients were allocated a clinical tumor stage before treatment, which was compared with pathologic stage after surgical resection. Survival analysis was conducted using Kaplan-Meier analysis and Cox regression analysis. Results Among 584 included patients, 400 patients (68%) received neoadjuvant chemotherapy. Patients with downstaged tumors after neoadjuvant chemotherapy experienced improved survival compared with patients without response (P < .001), and such downstaging (hazard ratio, 0.43; 95% CI, 0.31 to 0.59) was the strongest independent predictor of survival after adjusting for patient age, tumor grade, clinical tumor stage, lymphovascular invasion, resection margin status, and surgical resection type. Patients downstaged by chemotherapy, compared with patients with no response, experienced lower rates of local recurrence (6% v 13%, respectively; P = .030) and systemic recurrence (19% v 29%, respectively; P = .027) and improved Mandard tumor regression scores (P = .001). Survival was strongly dictated by stage after neoadjuvant chemotherapy, rather than clinical stage at presentation. Conclusion The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvant chemotherapy determines prognosis rather than the clinical stage before neoadjuvant chemotherapy, indicating the importance of focusing on postchemotherapy staging to more accurately predict outcome and eligibility for surgery. Patients who are downstaged by neoadjuvant chemotherapy benefit from reduced rates of local and systemic recurrence. (C) 2014 by American Society of Clinical Oncolog